Skip to content

US · MDCXW · BIOTECHNOLOGY

Medicus Pharma Ltd. Common Stock (MDCXW) intrinsic value and stock valuation

$0.68as of 2026-09-18 · Mkt cap 7.49M

Data updated · price as of 2026-09-18

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Medicus Pharma Ltd. Common Stock DCF and intrinsic value

InvestorsCraft values MDCXW with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MDCXW’s statements →

Medicus Pharma Ltd. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology West Conshohocken, PA, CA medicuspharma.com

How the business is doing

Fiscal 2025–2021, USD

Revenue
$0.00
20252021
Net income
-$-2.06T
20252021
Free cash flow
-$-1.45T
20252021
Total equity
-$-10.51T
20252021

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2025–2021, USD
FYFYFYFYFY
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-18.35T-$-11.18T-$-4.73T-$-978.42B-$-1.44T
Net income-$-25.37T-$-11.16T-$-5.31T-$-1.69T-$-2.06T
EPSd-$-1.47M-$-944.04K-$-658.04K-$-209.54K-$-255.35K
Operating cash flow-$-22.78T-$-10.25T-$-4.16T-$-1.06T-$-1.45T
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-22.78T-$-10.25T-$-4.16T-$-1.06T-$-1.45T
Total assets$10.1T$5.65T$1.89T$282.7B$78.5B
Total debt$4T$322.3B$0.00$1.53T$667.9B
Net debt-$-4.71T-$-3.84T-$-1.72T$1.26T$589.4B
Total equity$37.3B$3.13T$1.11T-$-12.2T-$-10.51T
Cash and short-term investments$8.71T$4.16T$1.72T$267.7B$78.5B
Income statement
FYFYFYFYFY
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$7.72T$3.53T$193.6B$646.4B$1.18T
Selling, general and administrative expenses$17.9T$7.65T$2.46T$332B$258B
Other expenses-$-7.29T$0.00$2.07T$0.00$0.00
Operating expenses$18.4T$11.2T$4.73T$978.4B$1.44T
Cost and expenses$18.4T$11.2T$4.73T$978.4B$1.44T
Interest income$0.00$104.4B$10.7B-$-575.45B-$-575.45B
Interest expense$141.3B$317.5B$595.5B$526.8B$115.4B
Depreciation and amortization$0.00$0.00$2.07T$0.00$0.00
Ebitda-$-25.23T-$-11.16T-$-586.79B-$-1.17T-$-1.94T
Operating income-$-18.35T-$-11.18T-$-4.73T-$-978.42B-$-1.44T
Total other income/expenses, net-$-7.02T$25.4B-$-584.82B-$-713.97B-$-613.88B
Income before tax-$-25.37T-$-11.16T-$-5.31T-$-1.69T-$-2.06T
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-25.37T-$-11.16T-$-5.31T-$-1.69T-$-2.06T
Weighted average shares outstanding$17.3T$11.8T$8.08T$8.08T$8.05T
Weighted average diluted shares outstanding$17.3T$11.8T$8.08T$8.08T$8.05T
Balance sheet
FYFYFYFYFY
Cash and short-term investments$8.71T$4.16T$1.72T$267.7B$78.5B
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$9.89T$5.38T$1.89T$282.7B$78.5B
Property, plant and equipment, net$170.7B$268.6B$0.00$0.00$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$170.7B$268.6B$0.00$0.00$0.00
Total assets$10.1T$5.65T$1.89T$282.7B$78.5B
Accounts payable$3.44T$1.28T$210.8B$0.00$0.00
Short-term debt$3.93T$116.3B$0.00$1.53T$667.9B
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$9.94T$2.31T$781.6B$12.5T$10.6T
Long-term debt$62.7B$205.8B$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$62.7B$205.9B$0.00$0.00$0.00
Capital lease obligations$43.9B$205.8B$0.00$0.00$0.00
Total liabilities$10T$2.51T$781.6B$12.5T$10.6T
Common stock$57.1T$30.5T$18.8T$194.5B$194.5B
Retained earnings-$-64.35T-$-28.9T-$-17.75T-$-12.39T-$-10.7T
Accumulated other comprehensive income (loss)$10.9B$0.00$0.00$0.00$0.00
Total equity$37.3B$3.13T$1.11T-$-12.2T-$-10.51T
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$4T$322.3B$0.00$1.53T$667.9B
Net debt-$-4.71T-$-3.84T-$-1.72T$1.26T$589.4B
Cash flow statement
FYFYFYFYFY
Net income-$-35.44T-$-11.16T-$-5.31T-$-1.69T-$-2.06T
Depreciation and amortization$0.00$0.00$0.00$0.00$0.00
Stock-based compensation$1.51T$713.1B$98.6B$0.00$0.00
Change in working capital$407.7B$32.9B$473.1B-$-78.69B-$-6.66B
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$0.00$808.7B$79.1B$0.00$0.00
Net cash provided by operating activities-$-22.78T-$-10.25T-$-4.16T-$-1.06T-$-1.45T
Investments in property, plant and equipment$0.00$0.00$0.00$0.00$0.00
Acquisitions, net-$-4.62T$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-4.62T$0.00$0.00$0.00$0.00
Common stock issued$19.8T$7.52T$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$31.9T$12.7T$5.61T$1.25T$882.4B
Net change in cash$4.54T$2.44T$1.45T$189.1B-$-565.66B
Cash at end of period$8.71T$4.16T$1.72T$267.7B$78.5B
Operating cash flow-$-22.78T-$-10.25T-$-4.16T-$-1.06T-$-1.45T
Capital expenditure$0.00$0.00$0.00$0.00$0.00
Free cash flow-$-22.78T-$-10.25T-$-4.16T-$-1.06T-$-1.45T
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Medicus Pharma Ltd. Common Stock

        Medicus Pharma Ltd. is a biotech life sciences company, which focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. It develops a product, SkinJectTM, with an indication for basal cell carcinoma. The company was founded on April 30, 2008 and is headquartered in Toronto, Canada.

        CEO
        Raza Bokhari
        Employees
        16
        Beta
        -0.65

        Explore

        Frequently asked questions

        What is the intrinsic value of Medicus Pharma Ltd. Common Stock (MDCXW)?

        InvestorsCraft does not currently publish an intrinsic value for MDCXW. How the IC value is calculated.

        Is MDCXW undervalued?

        InvestorsCraft does not publish an undervaluation signal for MDCXW at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Sep 19, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.